NewsBenzingaPDS Biotechnology annuncia la pubblicazione dei risultati dello studio di fase 2 che valuta PDS0101, immunoterapia mirata all'HPV16, in combinazione con Pembrolizumab su JAMA Oncology, rivista peer-reviewed dell'American Medical Association PDS Biotechnology annuncia la pubblicazione dei risultati dello studio di fase 2 che valuta PDS0101, immunoterapia mirata all'HPV16, in combinazione con Pembrolizumab su JAMA Oncology, rivista peer-reviewed dell'American Medical Association Benzinga 2026.09.22 12:08 (GMT+0) Open on Benzinga Other news Tolan snags $30M for its AI companion that helps users navigate life Replika’s founder built the AI assistant she pitched at Disrupt 12 years ago Tenstorrent hits $6.2B valuation to scale open-weight AI chips Homebuilder Sentiment Hits 2012 Lows As Stocks Trade Like They Did During COVID-19 Pandemic Rain Says Western Union's Stablecard Is Live in 37 Markets FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated
